CL2015001127A1 - Nuevas variantes del receptor iib de fc gamma - Google Patents

Nuevas variantes del receptor iib de fc gamma

Info

Publication number
CL2015001127A1
CL2015001127A1 CL2015001127A CL2015001127A CL2015001127A1 CL 2015001127 A1 CL2015001127 A1 CL 2015001127A1 CL 2015001127 A CL2015001127 A CL 2015001127A CL 2015001127 A CL2015001127 A CL 2015001127A CL 2015001127 A1 CL2015001127 A1 CL 2015001127A1
Authority
CL
Chile
Prior art keywords
receiver
new variants
gamma iib
iib
gamma
Prior art date
Application number
CL2015001127A
Other languages
English (en)
Spanish (es)
Inventor
Peter Sondermann
Meer Dominik Ter
Thomas Pohl
Reno Winter
Uwe Jacob
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of CL2015001127A1 publication Critical patent/CL2015001127A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
CL2015001127A 2012-10-30 2015-04-29 Nuevas variantes del receptor iib de fc gamma CL2015001127A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Publications (1)

Publication Number Publication Date
CL2015001127A1 true CL2015001127A1 (es) 2015-12-18

Family

ID=49679480

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001127A CL2015001127A1 (es) 2012-10-30 2015-04-29 Nuevas variantes del receptor iib de fc gamma

Country Status (27)

Country Link
US (1) US10028998B2 (enExample)
EP (1) EP2914624B1 (enExample)
JP (2) JP6423351B2 (enExample)
KR (1) KR102170674B1 (enExample)
CN (1) CN104918955B (enExample)
AU (1) AU2013340831B2 (enExample)
BR (1) BR112015008815A2 (enExample)
CA (1) CA2887164C (enExample)
CL (1) CL2015001127A1 (enExample)
DK (1) DK2914624T3 (enExample)
EA (1) EA033437B9 (enExample)
ES (1) ES2628049T3 (enExample)
HR (1) HRP20170894T1 (enExample)
HU (1) HUE032786T2 (enExample)
IL (1) IL238528A (enExample)
IN (1) IN2015DN03206A (enExample)
LT (1) LT2914624T (enExample)
MX (1) MX359802B (enExample)
MY (1) MY173686A (enExample)
NZ (1) NZ706884A (enExample)
PH (1) PH12015500771B1 (enExample)
PL (1) PL2914624T3 (enExample)
PT (1) PT2914624T (enExample)
RS (1) RS56075B1 (enExample)
SG (1) SG11201502749VA (enExample)
SI (1) SI2914624T1 (enExample)
WO (1) WO2014068012A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
EA034176B1 (ru) 2013-10-16 2020-01-14 Зуппремоль Гмбх РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えFcγRIIb
CN112423900A (zh) * 2018-06-25 2021-02-26 巴斯夫涂料有限公司 生产优化涂层的方法和使用所述方法可获得的涂层
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434447T2 (de) 1993-06-07 2006-05-18 Vical, Inc., San Diego Für die gentherapie verwendbare plasmide
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) * 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2004293184B2 (en) 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
DE602006020333D1 (de) 2005-12-13 2011-04-07 Suppremol Gmbh Multimere fc-rezeptor-polypeptide
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CN102131517B (zh) 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Also Published As

Publication number Publication date
JP2016503289A (ja) 2016-02-04
JP2018186833A (ja) 2018-11-29
CN104918955A (zh) 2015-09-16
IL238528A (en) 2017-07-31
MX2015005266A (es) 2015-10-26
PL2914624T3 (pl) 2017-09-29
KR20150122621A (ko) 2015-11-02
IN2015DN03206A (enExample) 2015-10-02
WO2014068012A1 (en) 2014-05-08
CA2887164C (en) 2020-12-29
EP2914624B1 (en) 2017-03-15
PT2914624T (pt) 2017-06-07
KR102170674B1 (ko) 2020-10-28
HK1209765A1 (en) 2016-04-08
IL238528A0 (en) 2015-06-30
BR112015008815A2 (pt) 2017-11-21
EA033437B9 (ru) 2020-03-19
AU2013340831A1 (en) 2015-04-30
RS56075B1 (sr) 2017-10-31
CN104918955B (zh) 2018-10-09
US20140120080A1 (en) 2014-05-01
ES2628049T3 (es) 2017-08-01
EA033437B1 (ru) 2019-10-31
NZ706884A (en) 2019-05-31
AU2013340831B2 (en) 2017-11-23
EP2914624A1 (en) 2015-09-09
US10028998B2 (en) 2018-07-24
JP6423351B2 (ja) 2018-11-14
MY173686A (en) 2020-02-15
SI2914624T1 (sl) 2017-07-31
HUE032786T2 (en) 2017-10-30
HRP20170894T1 (hr) 2017-09-08
CA2887164A1 (en) 2014-05-08
PH12015500771A1 (en) 2015-06-08
LT2914624T (lt) 2017-06-26
EA201590845A1 (ru) 2015-08-31
DK2914624T3 (en) 2017-06-26
SG11201502749VA (en) 2015-05-28
MX359802B (es) 2018-10-10
PH12015500771B1 (en) 2018-12-14

Similar Documents

Publication Publication Date Title
CL2015001127A1 (es) Nuevas variantes del receptor iib de fc gamma
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12018500386B1 (en) Il-8-binding antibodies and uses thereof
IL255790A (en) Device and system and to culture cells and methods for using them
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
IN2015KN00007A (enExample)
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MY193661A (en) Anti-tim3 antibodies and methods of use
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
EA201691991A1 (ru) Мультиспецифические антитела
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
MX2019012708A (es) Anticuerpos teicoicos anti-pared y conjugados.
MX2015016354A (es) Anticuerpos anti-acido teicoico de pared y conjugados.
PL3636277T3 (pl) Peptydy, urządzenia i sposoby wykrywania przeciwciał anaplasma
EP3244910A4 (en) Cell penetrating antibodies
EP3255137A4 (en) Cell culture system
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
EP3888671A3 (en) Protein formulations